The Taiwan Ministry of Health reported that Taiwan’s population will increase till 2021, along with an increase in the population of seniors. As a result, national health expenditure will continue to increase. In 2017 , Taiwan’s national health expenditure amounted to US $37.5 billion, which is 6.4% of gross domestic product (GDP), which represents an increase of 3.7% over the previous year. About 60.8% of Taiwan’s healthcare expenditures are funded by the public sector, with the remaining 39.6% covered by the private sector.
Pharma14 covers over 40,000 registered medicines in Taiwan including ex-factory tender pricing information.
Sample Taiwan data: Trastuzumab. Ex-factory tender pricing.
14 Shenkar st.